Hello everybody, just as an FYI.
I just read that teh novel drug, BNT316/ONC-392 (Gotistobart), from BioNTech has increased the survival of non-small cell lung cancer ( a difficult to treat and common long tumor) patients by 50% to that conventional chemotherapy. (conventional OS 10months, Gotistobart endpoint of OS nach 15months not achieved).
Gotistobart is a combination medication of an antibody up-regulating CTLA-4 in T-cells in the tumor microenvironment and thus working against downregulation of the immune system by the cancer, and an angiogenesis inhibitor (similar to avastin). BioNTech (which is the company who developed mRNA vaccine against COVID-19) put great effort into this, buying the chinese company OncoC4 to fast track the development of this drug. This drug is non only being tested for lung cancer in phase 3 trials (including Canada), but also in other cancers, such as platinresistent ovarian cancer.
ClinicalTrials.gov (PRESERVE-004; NCT05446298) - here in combination with pembrolizumab
This is absolutely encouraging and worth following the story.
-------------------------------------------